Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed NSCLC that is locally advanced and unresectable.
Adequate tumor sample from fresh biopsy or archival tissue block must be available.
Evaluable disease per RECIST v1.1.
Eastern Cooperative Oncology Group performance status 0 to 1.
Willingness to avoid pregnancy or fathering children.
You may not be if
Receipt of cancer treatment for this malignancy, including but not limited to radiation therapy, investigational agents, chemotherapy, and immunotherapy for disease under consideration.
Recent major surgery within 4 weeks before entry into the study.
Any medical contraindication to platinum-based doublet chemotherapy.
Active autoimmune disease requiring systemic immunosuppression in excess of physiologic consolidation doses of corticosteroids (\> 10 mg/day of prednisone or equivalent).
Known hypersensitivity to another monoclonal antibody that cannot be controlled with standard measures (eg, antihistamines and corticosteroids).
Mixed small cell and NSCLC histology.
Evidence of interstitial lung disease or active noninfectious pneumonitis.
Participants who are HIV-positive.
History of organ transplant, including allogeneic stem cell transplantation.
